$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

$nmtc Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000121390023010739 Filed on February 13, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2021 Q4
Revenue	$466.2K	$114.6K	$40.12K
YoY Change	1174.4%	185.59%	-57.21%
Cost Of Revenue	$434.7K	$126.9K	$46.84K
YoY Change	497.0%	170.89%	-57.08%
Gross Profit	$31.50K	-$12.31K	-$6.720K
YoY Change	-186.95%	83.14%	-56.31%
Gross Profit Margin	6.76%	-10.74%	-16.75%
Selling, General & Admin	$1.821M	$1.664M	$1.742M
YoY Change	0.16%	-4.5%	45.92%
% of Gross Profit	5780.74%
Research & Development	$1.706M	$1.563M	$1.060M
YoY Change	41.56%	47.44%	14.03%
% of Gross Profit	5416.35%
Depreciation & Amortization	$38.33K	$35.89K	$25.16K
YoY Change	34.35%	42.64%	34.26%
% of Gross Profit	121.67%
Operating Expenses	$3.527M	$3.227M	$2.803M
YoY Change	16.66%	15.15%	31.7%
Operating Profit	-$3.496M	-$1.784M	-$2.809M
YoY Change	14.25%	-36.48%	31.07%
Interest Expense			$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	-$26.91K	$51.58K	$1.850K
YoY Change	-1646.55%	2688.11%	-99.0%
Pretax Income	-$3.523M	-$1.733M	-$2.807M
YoY Change	15.2%	-38.28%	43.28%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$3.523M	-$1.733M	-$2.807M
YoY Change	15.2%	-38.28%	43.28%
Net Earnings / Revenue	-755.69%	-1512.29%	-6997.69%
Basic Earnings Per Share	-$0.21	-$0.11	-$0.18
Diluted Earnings Per Share	-$0.21	-$0.11	-$182.2K
COMMON SHARES
Basic Shares Outstanding	16.36M shares	16.24M shares	15.41M shares
Diluted Shares Outstanding	16.41M shares	16.23M shares	15.41M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.598M	$7.643M	$16.18M
YoY Change	-64.27%	-52.78%	127.02%
Cash & Equivalents	$3.602M	$4.667M	$16.18M
Short-Term Investments	$995.4K	$2.975M
Other Short-Term Assets	$370.7K	$325.5K	$137.5K
YoY Change	17.65%	136.79%	9.22%
Inventory	$1.174M	$903.6K	$229.1K
Prepaid Expenses	$370.7K	$325.5K
Receivables	$214.0K	$95.32K	$24.63K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$6.357M	$8.967M	$16.58M
YoY Change	-52.71%	-45.9%	125.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$522.8K	$334.8K	$479.3K
YoY Change	-0.04%	-30.15%	13.63%
Goodwill
YoY Change
Intangibles	$100.7K	$106.3K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$848.5K	$693.2K	$607.9K
YoY Change	31.35%	14.03%	6.14%
TOTAL ASSETS
Total Short-Term Assets	$6.357M	$8.967M	$16.58M
Total Long-Term Assets	$848.5K	$693.2K	$607.9K
Total Assets	$7.205M	$9.660M	$17.18M
YoY Change	-48.86%	-43.78%	117.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$953.4K	$861.6K	$703.7K
YoY Change	113.77%	22.44%	35.46%
Accrued Expenses	$596.9K	$473.1K	$356.4K
YoY Change	64.92%	32.75%	-41.76%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.550M	$1.335M	$1.062M
YoY Change	91.35%	25.64%	-82.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$121.9K	$153.7K	$173.3K
YoY Change	-21.88%	-11.3%	-46.23%
Total Long-Term Liabilities	$121.9K	$153.7K	$173.3K
YoY Change	-21.88%	-11.3%	-46.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.550M	$1.335M	$1.062M
Total Long-Term Liabilities	$121.9K	$153.7K	$173.3K
Total Liabilities	$1.672M	$1.488M	$1.236M
YoY Change	73.07%	20.46%	-81.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$56.10M	-$52.56M
YoY Change
Common Stock	$16.89K	$16.24K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.533M	$8.172M	$15.95M
YoY Change
Total Liabilities & Shareholders Equity	$7.205M	$9.660M	$17.18M
YoY Change	-48.86%	-43.78%	117.15%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2021 Q4
OPERATING ACTIVITIES
Net Income	-$3.523M	-$1.733M	-$2.807M
YoY Change	15.2%	-38.28%	43.28%
Depreciation, Depletion And Amortization	$38.33K	$35.89K	$25.16K
YoY Change	34.35%	42.64%	34.26%
Cash From Operating Activities	-$3.552M	-$3.492M	-$2.679M
YoY Change	10.24%	30.35%	40.69%
INVESTING ACTIVITIES
Capital Expenditures	$175.7K	$11.51K	-$61.49K
YoY Change	-288.28%	-118.72%
Acquisitions
YoY Change
Other Investing Activities	$2.000M	$26.58K
YoY Change
Cash From Investing Activities	$1.824M	$15.07K	-$61.49K
YoY Change	-2054.9%	-124.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	662.0K	-$15.71K	12.02M
YoY Change	-206962.5%	-100.13%	140.62%
NET CHANGE
Cash From Operating Activities	-3.552M	-$3.492M	-2.679M
Cash From Investing Activities	1.824M	$15.07K	-61.49K
Cash From Financing Activities	662.0K	-$15.71K	12.02M
Net Change In Cash	-1.065M	-$3.493M	9.283M
YoY Change	-67.87%	-137.63%	200.16%
FREE CASH FLOW
Cash From Operating Activities	-$3.552M	-$3.492M	-$2.679M
Capital Expenditures	$175.7K	$11.51K	-$61.49K
Free Cash Flow	-$3.727M	-$3.504M	-$2.618M
YoY Change	19.15%	33.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	dei	Document Type DocumentType	10-Q
CY2022Q4	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q4	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022Q4	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q4	dei	Entity File Number EntityFileNumber	001-40439
CY2022Q4	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q4	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-0863354
CY2022Q4	dei	Entity Address Address Line1 EntityAddressAddressLine1	7599 Anagram Drive
CY2022Q4	dei	Entity Address City Or Town EntityAddressCityOrTown	Eden Prairie
CY2022Q4	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2022Q4	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55344
CY2022Q4	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
CY2022Q4	dei	Trading Symbol TradingSymbol	NMTC
CY2022Q4	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q4	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q4	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q4	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q4	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q4	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16363946	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4667432	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8160329	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	2975194	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	2981010	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	95319	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	33237	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	903554	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	704538	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	325488	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	296649	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	8966987	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	12175763	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	106313	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	111892	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	252119	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	181355	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	334801	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	353599	usd
CY2022Q4	us-gaap	Assets Assets	9660220	usd
CY2022Q3	us-gaap	Assets Assets	12822609	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	861638	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	927662	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	473085	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	715839	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	1455188	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1334723	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3098689	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	153721	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	119556	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1488444	usd
CY2022Q3	us-gaap	Liabilities Liabilities	3218245	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16238464	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16238464	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16216540	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16216540	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	16239	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	16217	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60715118	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60414959	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52559581	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50826812	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	8171776	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9604364	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9660220	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12822609	usd
CY2022Q4	us-gaap	Revenues Revenues	114579	usd
CY2021Q4	us-gaap	Revenues Revenues	33748	usd
CY2022Q4	us-gaap	Cost Of Revenue CostOfRevenue	126886	usd
CY2021Q4	us-gaap	Cost Of Revenue CostOfRevenue	46844	usd
CY2022Q4	us-gaap	Gross Profit GrossProfit	-12307	usd
CY2021Q4	us-gaap	Gross Profit GrossProfit	-13096	usd
CY2022Q4	nmtc	Revenue From Collaboration RevenueFromCollaboration	1455188	usd
CY2021Q4	nmtc	Revenue From Collaboration RevenueFromCollaboration	6374	usd
CY2022Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1663737	usd
CY2021Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1742141	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1563496	usd
CY2021Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1060462	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	3227233	usd
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	2802603	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1784352	usd
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2809325	usd
CY2022Q4	us-gaap	Other Income OtherIncome	51583	usd
CY2021Q4	us-gaap	Other Income OtherIncome	1850	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1732769	usd
CY2021Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2807475	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-1732769	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-2807475	usd
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16230997	shares
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15408480	shares
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	6553901	usd
CY2021Q4	nmtc	Issuance Of Warrants In Connections With Convertible Notes Offering IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering	13350582	usd
CY2021Q4	nmtc	Issuance Cost In Connection With Public Offering IssuanceCostInConnectionWithPublicOffering	1352280	usd
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	203072	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-2807475	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15947800	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9604364	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	300181	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-1732769	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8171776	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-1732769	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-2807475	usd
CY2022Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	35889	usd
CY2021Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25161	usd
CY2022Q4	nmtc	Allocated Share Based Compensation AllocatedShareBasedCompensation	300181	usd
CY2021Q4	nmtc	Allocated Share Based Compensation AllocatedShareBasedCompensation	203072	usd
CY2022Q4	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	20765	usd
CY2022Q4	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-26772	usd
CY2021Q4	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-26235	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	62082	usd
CY2021Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-23708	usd
CY2022Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	199016	usd
CY2021Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	130828	usd
CY2022Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-74948	usd
CY2021Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-13649	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-154098	usd
CY2021Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	291172	usd
CY2022Q4	nmtc	Increase Decrease Deferred Revenue IncreaseDecreaseDeferredRevenue	1455188	usd
CY2021Q4	nmtc	Increase Decrease Deferred Revenue IncreaseDecreaseDeferredRevenue	6374	usd
CY2022Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-306125	usd
CY2021Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-317456	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3492253	usd
CY2021Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2679136	usd
CY2022Q4	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1473419	usd
CY2022Q4	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	1500000	usd
CY2022Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11512	usd
CY2021Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	61491	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15069	usd
CY2021Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-61491	usd
CY2021Q4	nmtc	Proceeds From Issuance Of Common Stock In Connection With Private Placement ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement	13350582	usd
CY2022Q4	nmtc	Deferreds Offering Costs DeferredsOfferingCosts	-15713	usd
CY2021Q4	nmtc	Deferreds Offering Costs DeferredsOfferingCosts	-1326978	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-15713	usd
CY2021Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12023604	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3492897	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	9282977	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8160329	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6901346	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4667432	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16184323	usd
CY2022Q4	nmtc	Unpaid Deferred Offering Costs UnpaidDeferredOfferingCosts	88074	usd
CY2021Q4	nmtc	Unpaid Deferred Offering Costs UnpaidDeferredOfferingCosts	322	usd
CY2022Q4	nmtc	Operating Lease Right Of Use Asset Obtained In Exchange For Operating Lease OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease	97536	usd
CY2021Q4	nmtc	Reclass Of Deferred Offering Costs To Additional Paidin Capital In Connection With Public Offering ReclassOfDeferredOfferingCostsToAdditionalPaidinCapitalInConnectionWithPublicOffering	24980	usd
CY2022Q4	us-gaap	Cumulative Earnings Deficit CumulativeEarningsDeficit	52600000	usd
CY2022Q4	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management’s Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q3	nmtc	Royalty Minimum Payments Year Three RoyaltyMinimumPaymentsYearThree	150000	usd
CY2022	nmtc	Royalty Fee RoyaltyFee	37500	usd
CY2021	nmtc	Royalty Fee RoyaltyFee	25000	usd
CY2022Q4	nmtc	Warrantshares Warrantshares	7103344	shares
CY2021Q4	nmtc	Warrantshares Warrantshares	6753444	shares
CY2022Q4	nmtc	Stock Options StockOptions	1313646	shares
CY2021Q4	nmtc	Stock Options StockOptions	1111226	shares
CY2022Q4	nmtc	Restricted Stock Unit RestrictedStockUnit	392500	shares
CY2021Q4	nmtc	Restricted Stock Unit RestrictedStockUnit	6888	shares
CY2022Q4	nmtc	Unissued Vested Restricted Stock Units UnissuedVestedRestrictedStockUnits	7322	shares
CY2020Q3	nmtc	Royalty Minimum Payments Year One RoyaltyMinimumPaymentsYearOne	50000	usd
CY2021Q3	nmtc	Royalty Minimum Payments Year Two RoyaltyMinimumPaymentsYearTwo	100000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	153721	usd
CY2022Q4	nmtc	Lease Agreement Description LeaseAgreementDescription	The initial base rent for the Premises is $6,410 per month for the first 17 months, increasing to $7,076 per month by the end of the Term. In addition, as long as the Company is not in default under the Lease, the Company shall be entitled to an abatement of its base rent for the first 5 months. In addition, the Company will pay its pro rata share of the Landlord’s annual operating expenses associated with the premises, calculated as set forth in the Lease of which the Company is entitled to an abatement of these operating expense for the first 3 months.
CY2021Q3	nmtc	Lease Space LeaseSpace	1162	sqm
CY2021Q3	nmtc	Lease Rental Expense LeaseRentalExpense	4241	usd
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P2Y
CY2023Q1	nmtc	Lease Rental Expense LeaseRentalExpense	4453	usd
CY2022Q4	nmtc	Rent Expense RentExpense	42474	usd
CY2021Q4	nmtc	Rent Expense RentExpense	43045	usd
CY2022Q4	nmtc	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	32928	usd
CY2021Q4	nmtc	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	32435	usd
CY2022Q4	nmtc	Operating Leases OperatingLeases	97536	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	252119	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	181355	usd
CY2022Q4	nmtc	Lease Liability LeaseLiability	272405	usd
CY2022Q3	nmtc	Lease Liability LeaseLiability	202895	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.078	pure
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.069	pure
CY2022Q4	nmtc	Lessee Operating Lease Liability Payments Due One Year LesseeOperatingLeaseLiabilityPaymentsDueOneYear	135773	usd
CY2022Q4	nmtc	Lessee Operating Lease Liability Payments Due Two Year LesseeOperatingLeaseLiabilityPaymentsDueTwoYear	139969	usd
CY2022Q4	nmtc	Lessee Operating Lease Liability Payments Due Three Year LesseeOperatingLeaseLiabilityPaymentsDueThreeYear	21227	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	296969	usd
CY2022Q4	nmtc	Imputed Interest ImputedInterest	-24564	usd
CY2022Q4	nmtc	Lease Liability Net LeaseLiabilityNet	272405	usd
CY2022Q4	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	118684	usd
CY2022Q4	nmtc	Prepaid Expenses PrepaidExpenses	221701	usd
CY2022Q3	nmtc	Prepaid Expenses PrepaidExpenses	296649	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	103787	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	325488	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	296649	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	903554	usd
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	630570	usd
CY2022Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	73968	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	903554	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	704538	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	111892	usd
CY2022Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5579	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	106313	usd
CY2022Q4	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	5579	usd
CY2021Q4	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	5579	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	549573	usd
CY2022Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	538061	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1895	usd
CY2022Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1895	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	551468	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	539956	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	216667	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	186357	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	334801	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	353599	usd
CY2022Q4	us-gaap	Depreciation Depreciation	30310	usd
CY2021Q4	us-gaap	Depreciation Depreciation	19582	usd
CY2022Q4	nmtc	Accrued Payroll AccruedPayroll	186517	usd
CY2022Q3	nmtc	Accrued Payroll AccruedPayroll	521368	usd
CY2022Q4	nmtc	Lease Liability Shortterms LeaseLiabilityShortterms	118684	usd
CY2022Q3	nmtc	Lease Liability Shortterms LeaseLiabilityShortterms	83339	usd
CY2022Q4	nmtc	Royalty Payments RoyaltyPayments	145883	usd
CY2022Q3	nmtc	Royalty Payments RoyaltyPayments	111132	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	22001	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	473085	usd
CY2022Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	715839	usd
CY2022Q4	nmtc	Intial Fee Payment IntialFeePayment	2000000	usd
CY2022Q4	nmtc	Aggregate Number Of Warrants Exercisable AggregateNumberOfWarrantsExercisable	350000	shares
CY2022Q4	us-gaap	Share Price SharePrice	3
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.029	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.535	pure
CY2022Q4	nmtc	Expected Term ExpectedTerm	P5Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q4	us-gaap	Business Development BusinessDevelopment	5400000	usd
CY2022Q4	nmtc	Initial Exclusivity Fee InitialExclusivityFee	2000000	usd
CY2022Q4	nmtc	Milestone Payments MilestonePayments	3500000	usd
CY2022Q4	nmtc	Fair Value Of Warrants FairValueOfWarrants	100000	usd
CY2021Q4	us-gaap	Business Development BusinessDevelopment	6374	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	1455188	usd
CY2021Q3	us-gaap	Deferred Revenue DeferredRevenue	8622	usd
CY2022Q4	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	1455188	usd
CY2021Q4	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	6374	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	2248	usd
CY2022Q4	nmtc	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	114579	usd
CY2021Q4	nmtc	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	33748	usd
CY2022Q4	us-gaap	Advertising Expense AdvertisingExpense	53026	usd
CY2022Q4	nmtc	Aggregate Offering Price AggregateOfferingPrice	14500000	usd
CY2022Q4	nmtc	Fixed Commission Rate FixedCommissionRate	0.03	pure
CY2022Q4	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	103787	usd
CY2021Q4	nmtc	Purchase Of Additional Shares PurchaseOfAdditionalShares	562500	shares
CY2021Q4	us-gaap	Advertising Expense AdvertisingExpense	61335	usd
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	300181	usd
CY2021Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	203072	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	73731	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1313646	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1239915	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.535	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.56	pure
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y1M6D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.04	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.011	pure
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1422392	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M18D
CY2022Q4	us-gaap	Concentration Risk Customer ConcentrationRiskCustomer	One
CY2021Q4	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q4	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q4	nmtc	Fullydiluted Shares Percentage fullydilutedSharesPercentage	0.13	pure
CY2022Q4	dei	Entity Registrant Name EntityRegistrantName	NEUROONE MEDICAL TECHNOLOGIES Corp
CY2022Q4	dei	Local Phone Number LocalPhoneNumber	426-1383
CY2022Q4	dei	City Area Code CityAreaCode	952
CY2021Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
CY2022Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
CY2021Q4	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
CY2021Q4	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments		usd
CY2022Q4	nmtc	Proceeds From Issuance Of Common Stock In Connection With Private Placement ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement		usd
CY2021Q4	nmtc	Operating Lease Right Of Use Asset Obtained In Exchange For Operating Lease OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease		usd
CY2022Q4	nmtc	Reclass Of Deferred Offering Costs To Additional Paidin Capital In Connection With Public Offering ReclassOfDeferredOfferingCostsToAdditionalPaidinCapitalInConnectionWithPublicOffering		usd
CY2021Q4	nmtc	Unissued Vested Restricted Stock Units UnissuedVestedRestrictedStockUnits		shares
CY2021Q4	nmtc	Operating Leases OperatingLeases		usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent		usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves		usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1		usd
CY2022Q4	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2022Q4	dei	Entity Central Index Key EntityCentralIndexKey	0001500198
CY2022Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023

Files In Submission

Name	View Source	Status
0001213900-23-010739-index-headers.html	Edgar Link	pending
0001213900-23-010739-index.html	Edgar Link	pending
0001213900-23-010739.txt	Edgar Link	pending
0001213900-23-010739-xbrl.zip	Edgar Link	pending
f10q1222ex31-1_neuroonemedi.htm	Edgar Link	pending
f10q1222ex31-2_neuroonemedi.htm	Edgar Link	pending
f10q1222ex32-1_neuroonemedi.htm	Edgar Link	pending
f10q1222ex32-2_neuroonemedi.htm	Edgar Link	pending
f10q1222_neuroonemedical.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nmtc-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nmtc-20221231_cal.xml	Edgar Link	unprocessable
nmtc-20221231_def.xml	Edgar Link	unprocessable
nmtc-20221231_lab.xml	Edgar Link	unprocessable
nmtc-20221231_pre.xml	Edgar Link	unprocessable
f10q1222_neuroonemedical_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

2023 Q1 Form 10-Q Financial Statement

#000121390023010739 Filed on February 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMTC NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

2023 Q1 Form 10-Q Financial Statement

#000121390023010739 Filed on February 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc